Brief: FDA Approves Lurbinectedin With Atezolizumab/Atezolizumab,Hyaluronidase-Tqjs For Type Of Lung Cancer
02/10/2025 20:40
Oct 2 (Reuters) - FDA: FDA APPROVES LURBINECTEDIN IN COMBINATION WITH ATEZOLIZUMAB OR ATEZOLIZUMAB AND HYALURONIDASE-TQJS FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER- WEBSITE Further company coverage: JAZZ.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jazz Pharmaceuticals
See all newsBrief: Jazz Pharmaceuticals Enters Amendment No. 4 To Credit Agreement On Sept 23, 2026
U.S. STOCKS ON THE MOVE-BWX Technologies, Synopsys,Burlington Stores
U.S. STOCKS ON THE MOVE-Jazz Pharmaceuticals, Celularity, Infleqtion
Jazz Pharma dips after upsized $1.1 bln convertible offering
Brief: Jazz Pharmaceuticals Announces Private Offering Of $1.0 Billion Of Exchangeable Senior Notes Due 2032